Hormonal
PT-141 (10mg) + Melanotan II (10mg) Stack Dosage Protocol
A two-vial stack combining central sexual arousal (PT-141) with melanocortin tanning and libido (Melanotan II) through complementary MC receptor profiles. Complete dosing guide and peer-reviewed references.
Last reviewed March 2025 · 2 cited sources
Reconstitution
Add 2.0 + 2.0 mL BAC water → 5 + 5 mg/mL
Dosing
PT-141 per event + MT-II loading/maintenance
Unit math (U-100 syringe)
See individual vial calculations
Storage (lyophilized)
Freeze at −4 °F · Reconstituted: 36–46 °F · Use within 28 days
Dosing & Reconstitution Guide
This stack protocol involves separate vials administered on different schedules. Refer to the table below for each component's dosing.
| Phase |
Component dose |
U-100 units |
Injection volume |
| PT-141 | 0.75–1.75 mg per event | 15–35 units | 0.15–0.35 mL |
| MT-II Loading | 100–250 mcg daily | 2–5 units | 0.02–0.05 mL |
| MT-II Maintenance | 50–100 mcg every 2–3 days | 1–2 units | 0.01–0.02 mL |
Route: Subcutaneous · Frequency: PT-141 per event; MT-II per loading protocol · Cycle: As needed
Reconstitution steps
01
Draw 2.0 + 2.0 mL of bacteriostatic water into a sterile syringe.
02
Inject the water slowly down the interior wall of the peptide vial -never directly onto the powder -to prevent foaming and denaturation.
03
Swirl or roll gently until fully dissolved. Do not shake. The lyophilized powder should dissolve completely within 30–60 seconds.
04
Label the vial with the reconstitution date and concentration (5 + 5 mg/mL). Refrigerate at 36–46 °F, protected from light. Use within 28 days.
Research use only. This protocol is derived from published preclinical and early-phase clinical literature. PT-141 (10mg) + Melanotan II (10mg) Stack is not FDA-approved for human use. This information is not medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before beginning any peptide protocol.
Supplies Needed
Estimates below assume the titration schedule listed above.
PT-141 (10mg) + Melanotan II (10mg) Stack vials (10mg + 10mg (two vials) each)
Per cycleAs needed per titration
U-100 insulin syringes
8 weeks56 syringes
12 weeks84 syringes
16 weeks112 syringes
Bacteriostatic water (10 mL bottles)
Per vial2.0 + 2.0 mL needed
Alcohol swabs (100-count boxes)
8 weeks2 boxes (~112 swabs)
12 weeks2 boxes (~168 swabs)
16 weeks3 boxes (~224 swabs)
Storage Instructions
Lyophilized (dry powder)
−4 °F
Store frozen in dry, dark conditions. Minimize humidity exposure. Stable for 12–24 months when properly stored.
Reconstituted (in solution)
36–46 °F
Refrigerate after reconstitution. Use within 28 days. Do not refreeze reconstituted solution -freeze-thaw cycles degrade peptide integrity.
Allow refrigerated vials to reach room temperature before opening to minimize condensation uptake. Always inspect for cloudiness or particulates before use -discard if present.
Looking for research-grade peptides? Pacific Edge Labs carries a growing catalog of high-purity compounds with third-party lab results published on each product page.
Why Pacific Edge Labs
- High-purity compounds with third-party lab results available on the website
- Consistent quality control with ISO-aligned handling and documentation
- Fast, discreet shipping with proper handling and packaging
Browse Pacific Edge Labs →
PT-141 (10mg) + Melanotan II (10mg) Stack is not currently in the PEL catalog -check back for availability.
How PT-141 (10mg) + Melanotan II (10mg) Stack Works
This stack coordinates PT-141 (bremelanotide) for per-event central sexual arousal with Melanotan II for ongoing tanning and baseline libido enhancement. While both act on melanocortin receptors, their usage patterns differ: PT-141 is dosed 1–2 hours before activity (not daily), while MT-II follows a loading/maintenance tanning protocol.
The independent vial approach allows each component to be dosed according to its specific protocol timing without compromising the other. PT-141 provides acute MC4R-mediated arousal, while MT-II provides chronic MC1R-mediated melanogenesis with supplementary MC4R libido support.
Observed Effects & Side Effect Profile
The following observations are derived from preclinical literature and limited early-phase human data. They do not constitute clinical claims.
Reported benefits (research literature)
- Independent dosing of each component for different timing needs
- PT-141: acute per-event arousal (FDA-approved as Vyleesi)
- MT-II: ongoing tanning + baseline libido maintenance
- Complementary MC receptor activation profiles
Known limitations & side effects
- MT-II is NOT FDA-approved and carries significant side effects
- Combined melanocortin stimulation increases blood pressure effects
- Nausea from both compounds -may compound during overlap
- Multiple simultaneous hormonal effects require monitoring
- New or changed moles require dermatological surveillance
Lifestyle Considerations
While the following suggestions are not protocol requirements, research on tissue repair and peptide efficacy consistently highlights these as factors that influence outcomes:
01
Protein intake. Collagen synthesis and tissue remodeling require adequate dietary protein. Research generally supports 1.6–2.2 g/kg/day during active recovery periods.
02
Sleep. The majority of tissue repair and growth hormone secretion occurs during deep sleep stages. 7–9 hours of quality sleep per night supports the biological environment in which recovery peptides operate.
03
Activity balance. Avoid complete immobilization (which impedes collagen remodeling) and overuse (which re-injures tissue). Progressive loading appropriate to the injury stage supports functional recovery.
04
Stress management. Elevated cortisol chronically impairs immune function and tissue repair. Evidence-based stress reduction techniques support the recovery environment.
Injection Technique
Standard subcutaneous injection guidance from clinical best-practice references.
01
Wash hands thoroughly. Clean your work surface. Gather all supplies before beginning.
02
Wipe the vial rubber stopper with a fresh alcohol swab. Allow it to dry completely before inserting a needle.
03
Draw the calculated dose volume into a sterile insulin syringe. Invert the syringe and tap to remove air bubbles; expel them before withdrawing the needle from the vial.
04
Select an injection site: abdomen (at least 2 inches from the navel), outer thigh, or upper outer arm. Clean with a fresh alcohol swab and allow to dry.
05
Pinch a fold of skin between thumb and forefinger. Insert the needle at a 45–90° angle depending on body fat thickness -45° for leaner individuals, 90° for more subcutaneous tissue.
06
Do not aspirate. Current clinical guidelines do not recommend aspiration for subcutaneous injections. Inject slowly and steadily over 2–3 seconds.
07
Wait 3–5 seconds after the plunger bottoms out before withdrawing the needle at the same angle. Apply gentle pressure with a clean swab -do not rub vigorously.
08
Rotate injection sites systematically with every dose. Reusing the same site repeatedly causes lipohypertrophy (hardened fat tissue) which reduces absorption consistency.
09
Dispose of used needles and syringes immediately in a puncture-resistant sharps container. Never recap needles by hand.
Important Notes
⚠
Research use only. PT-141 (10mg) + Melanotan II (10mg) Stack is not FDA-approved for human use. Human clinical data may be limited. Do not use without consulting a qualified healthcare professional.
◎
One syringe per injection. Never reuse needles or syringes. Each injection requires a fresh, sterile syringe to prevent contamination and infection risk.
⚠
Nausea common from both compounds
⚠
Blood pressure effects -avoid with cardiovascular disease
⚠
Monitor for new or changed moles
◎
Document your protocol. Record daily dose, injection site, and any observations. This supports consistency and allows you to identify patterns or issues over the course of the cycle.
◎
Inspect before each use. The reconstituted solution should be clear and colorless. Discard if cloudy, discolored, or if particulates are visible.
References
All dosing recommendations and mechanism descriptions on this page are derived from the following peer-reviewed publications and regulatory documents.
